Paul Young is Professor of Respiratory Technology at the Woolcock Medical Research Institute and has over 25 years' experience in the area of respiratory product characterisation, formulation, development and commercialisation.

Paul is additionally Professor of Commercialisation at Macquarie Business School, where he specialises in commercialisation, entrepreneurship, pharmaceutical, MedTech and deep-tech business creation. Paul has held academic roles as the Inaugural Chair of commercialisation at the University of Sydney and Deputy Executive Director of the Woolcock Institute of Medical Research. 

Paul is a strong believer in building an entrepreneurial and translation-focused ecosystem in Australia. He is on the Executive Board of Accelerating Australia. He is also a Director of Biodseign.Sydney and co-director of Sydney SPARK, two multidisciplinary training programs that support the development of innovative medical devices and therapeutics. These programs have already seen the formation of a number of spin-off companies and significant pharma license deals for commercialisation. 

Paul has established, or is on the board of directors of, numerous small-medium enterprises, including Nanopharm UK Ltd (founder and director 2000-2007), OzUK Ltd (Director 2016-), and Pivot Innovations (Director 2021-). Paul is Chief Executive officer of Ab Initio Pharma Pty Ltd, a pharmaceutical research and development company specialising in the formulation and good manufacturing practice (GMP) production of pharmaceutical products in Australia.

View Professor Young's academic profile at Macquarie University.